Latest total revenue for EFTRW: $0, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
eFFECTOR Therapeutics- Warrants (26/08/2026) (EFTRW) currently reports a total revenue of $0 as of June 2026. That compares with $160K in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore eFFECTOR Therapeutics- Warrants (26/08/2026)'s total revenue history and peer comparisons.
eFFECTOR Therapeutics- Warrants (26/08/2026)'s total revenue decreased from $160K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
eFFECTOR Therapeutics- Warrants (26/08/2026)'s total revenue of $0 is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
eFFECTOR Therapeutics- Warrants (26/08/2026) reported $0 in total revenue as of June 2026. That compares with $160K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for eFFECTOR Therapeutics- Warrants (26/08/2026), and consider following EFTRW for alerts when major investors trade the stock.